bcdiabetes.ca
Patient Care + Research + Clinical Trials

Dr. Tom Elliott MBBS, FRCPC
Medical Director

400 - 210 W Broadway
Vancouver, BC
V5Y 3W2 Canada

phone: 604.683.3734
fax: 604.628.3821
email: moa@bcdiabetes.ca

Maridebart Cafraglutide (Maritide) monthly vs semaglutide weekly on top of metformin +/- SGLT2 in T2D

Study location BCDiabetes: 400 - 210 West Broadway, Vancouver V5Y 3W2
Principal Investigators Dr. Tom Elliott
SubInvestigators : Dr Dale Clayton
SC & Primary Contact Marla Inducil MD P: 604-628-7253 x 7011 : minducil@bcdiabetes.ca
Back up SC: Hector Com MD; Glaiza Erfe MD and Alireza Moshiri MD
Summary: a phase 3, multicenter, randomized, active-controlled, open-label,parallel group, global trial that will compare the efficacy and safety of maridebart cafraglutide once every 4 weeks (Q4W) versus semaglutide once weekly (QW) in participants with T2DM who are inadequately controlled with metformin, +/- SGLT2i
Hypothesis: Maridebart cafraglutide (otherwise known as AMG 133) is a first-in-class, bispecific, peptide-antibody conjugate with functional activities that antagonize GIPR and agonize GLP-1R. As such, maridebart cafraglutide represents a new drug class within T2DM management, whose effects are mediated via a combined activation of the GLP-1R and GIPRi.
Eligible Participants include:

- ≥18 yrs of age
- BMI ≥ 25 kg/m2
- A1c ≥ 7.5- ≤ 10%
- No GLP-1 RA; DPP4i within 90 days of screening
- Only metformin and SGLT2i allowed

Treatment course and duration: Eighteen visits over 76 weeks
Odds of receiving active drug are: 1:1 subjects will receive either maridebart-cafraglutide 350 mg every 4 weeks or semaglutide 2mg weekly

Procedure	Treatment Period[a]																	
Week		2	4	8[b]	12	16	20	24[b]	28	32	36	40[b]	44	48	52[b]	56	60	64[b]	EOT[b,c]
Days	1[b]	15	29	57	85	113	141	169	197	225	253	281	309	337	365	393	421	449	
Window (Days)		± 3	± 3	± 7	± 7	± 7	± 7	± 7	± 7	± 7	± 7	± 7	± 7	± 7	± 7	± 7	± 7	± 7	

Study documents:
Protocol :
Short URL = https://bit.ly/4fjPArQ